Montgomery, AL (PRWEB) December 21, 2004
Tom Methvin, managing shareholder at Beasley Allen Law Firm, has called upon Pfizer to recall Celebrex. ÂOur firm has been watching the situation unfold over the past 4 years. In light of the recent findings which undeniably link Celebrex to greater heart-attack risks, it is time for Pfizer to act responsibly and pull the drug from the market,Â said Mr. Methvin at a recent press conference.
According to a clinical trial conducted by the National Cancer Institute (NCI) and Pfizer, Inc., patients taking 400 mg of the drug twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo. For patients in the trial taking 200 mg. twice daily, the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months.
These findings are similar to recent results from a study of Vioxx (rofecoxib), another drug in the same class. Vioxx was recently voluntarily recalled by Merck in September. Another drug in this class, Bextra (valdecoxib) has shown an increased risk for CV events in patients after heart surgery. Bextra and Celebrex are the only two selective COX-2 agents currently on the U.S. market.
While Pfizer announced today that it would halt advertising of the drug, it appears they had little choice in that decision. The Food and Drug Administration said on Friday that it was considering regulatory measures that could include severe label warnings or even requiring that the drug be withdrawn in the United States.
ÂPfizer will inevitably have to recall Celebrex,Â Mr. Methvin said, Âand I believe they are making a careless decision in not doing so immediately.Â
Andy Birchfield, Beasley AllenÂs lead Celebrex Litigation attorney, is spearheading the review of 383 cases, having filed 53 of those cases against Pfizer dating back to 2000.
For more information:
Andy Birchfield, Attorney
Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.
1-800-898-2034 toll free
Online Media Contact:
1-800-898-2343 toll free
# # #